First Time Loading...

Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 2.41 EUR 2.99% Market Closed
Updated: May 19, 2024

Intrinsic Value

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight... [ Read More ]

The intrinsic value of one IPH stock under the Base Case scenario is 6.12 EUR. Compared to the current market price of 2.41 EUR, Innate Pharma SA is Undervalued by 61%.

Key Points:
IPH Intrinsic Value
Base Case
6.12 EUR
Undervaluation 61%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Innate Pharma SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IPH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Innate Pharma SA

Provide an overview of the primary business activities
of Innate Pharma SA.

What unique competitive advantages
does Innate Pharma SA hold over its rivals?

What risks and challenges
does Innate Pharma SA face in the near future?

Summarize the latest earnings call
of Innate Pharma SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Innate Pharma SA.

Provide P/S
for Innate Pharma SA.

Provide P/E
for Innate Pharma SA.

Provide P/OCF
for Innate Pharma SA.

Provide P/FCFE
for Innate Pharma SA.

Provide P/B
for Innate Pharma SA.

Provide EV/S
for Innate Pharma SA.

Provide EV/GP
for Innate Pharma SA.

Provide EV/EBITDA
for Innate Pharma SA.

Provide EV/EBIT
for Innate Pharma SA.

Provide EV/OCF
for Innate Pharma SA.

Provide EV/FCFF
for Innate Pharma SA.

Provide EV/IC
for Innate Pharma SA.

Show me price targets
for Innate Pharma SA made by professional analysts.

What are the Revenue projections
for Innate Pharma SA?

How accurate were the past Revenue estimates
for Innate Pharma SA?

What are the Net Income projections
for Innate Pharma SA?

How accurate were the past Net Income estimates
for Innate Pharma SA?

What are the EPS projections
for Innate Pharma SA?

How accurate were the past EPS estimates
for Innate Pharma SA?

What are the EBIT projections
for Innate Pharma SA?

How accurate were the past EBIT estimates
for Innate Pharma SA?

Compare the revenue forecasts
for Innate Pharma SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Innate Pharma SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Innate Pharma SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Innate Pharma SA compared to its peers.

Compare the P/E ratios
of Innate Pharma SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Innate Pharma SA with its peers.

Analyze the financial leverage
of Innate Pharma SA compared to its main competitors.

Show all profitability ratios
for Innate Pharma SA.

Provide ROE
for Innate Pharma SA.

Provide ROA
for Innate Pharma SA.

Provide ROIC
for Innate Pharma SA.

Provide ROCE
for Innate Pharma SA.

Provide Gross Margin
for Innate Pharma SA.

Provide Operating Margin
for Innate Pharma SA.

Provide Net Margin
for Innate Pharma SA.

Provide FCF Margin
for Innate Pharma SA.

Show all solvency ratios
for Innate Pharma SA.

Provide D/E Ratio
for Innate Pharma SA.

Provide D/A Ratio
for Innate Pharma SA.

Provide Interest Coverage Ratio
for Innate Pharma SA.

Provide Altman Z-Score Ratio
for Innate Pharma SA.

Provide Quick Ratio
for Innate Pharma SA.

Provide Current Ratio
for Innate Pharma SA.

Provide Cash Ratio
for Innate Pharma SA.

What is the historical Revenue growth
over the last 5 years for Innate Pharma SA?

What is the historical Net Income growth
over the last 5 years for Innate Pharma SA?

What is the current Free Cash Flow
of Innate Pharma SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Innate Pharma SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Innate Pharma SA

Current Assets 148m
Cash & Short-Term Investments 92.5m
Receivables 46.5m
Other Current Assets 9.1m
Non-Current Assets 36.2m
Long-Term Investments 9.8m
PP&E 6.3m
Intangibles 416k
Other Non-Current Assets 19.6m
Current Liabilities 39.6m
Accounts Payable 25.6m
Accrued Liabilities 7m
Short-Term Debt 7.1m
Other Current Liabilities -54k
Non-Current Liabilities 92.7m
Long-Term Debt 76m
Other Non-Current Liabilities 16.7m
Efficiency

Earnings Waterfall
Innate Pharma SA

Revenue
51.9m EUR
Cost of Revenue
-2.9m EUR
Gross Profit
49m EUR
Operating Expenses
-61.7m EUR
Operating Income
-12.7m EUR
Other Expenses
5.1m EUR
Net Income
-7.6m EUR

Free Cash Flow Analysis
Innate Pharma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

IPH Profitability Score
Profitability Due Diligence

Innate Pharma SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
Positive 1-Year Revenue Growth
27/100
Profitability
Score

Innate Pharma SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

IPH Solvency Score
Solvency Due Diligence

Innate Pharma SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
48/100
Solvency
Score

Innate Pharma SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 6.71 EUR with a low forecast of 2.27 EUR and a high forecast of 13.65 EUR.

Lowest
Price Target
2.27 EUR
6% Downside
Average
Price Target
6.71 EUR
178% Upside
Highest
Price Target
13.65 EUR
466% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Innate Pharma SA

Shareholder Return

IPH Price
Innate Pharma SA

1M 1M
+14%
6M 6M
+3%
1Y 1Y
-12%
3Y 3Y
-26%
5Y 5Y
-59%
10Y 10Y
-62%
Annual Price Range
2.41
52w Low
2.11
52w High
3.26
Price Metrics
Average Annual Return -8.69%
Standard Deviation of Annual Returns 33.48%
Max Drawdown -73%
Shares Statistics
Market Capitalization 194.8m EUR
Shares Outstanding 80 841 988
Percentage of Shares Shorted
N/A

IPH Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Innate Pharma SA Logo
Innate Pharma SA

Country

France

Industry

Biotechnology

Market Cap

194.8m EUR

Dividend Yield

0%

Description

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Contact

PACA
Marseille
117 avenue de Luminy, Bp 30191
+33430303030.0
http://www.innate-pharma.com

IPO

2006-10-31

Employees

215

Officers

Co-Founder, Interim CEO & Chairman of Executive Board
Dr. Herve Brailly Ph.D.
Executive VP, COO & Member of Executive Board
Mr. Yannis Morel Ph.D.
Founder, Senior VP & Chief Scientific Officer
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.
Founder
Mr. Alessandro Moretta M.D., Ph.D.
Senior VP & CFO
Mr. Frederic Lombard M.B.A.
Executive VP, Chief Medical Officer & Member of Executive Board
Dr. Sonia Quaratino M.D., Ph.D.
Show More
Executive VP, President of US Operations & Member of Executive Board
Mr. Arvind Sood
Show Less

See Also

Discover More
What is the Intrinsic Value of one IPH stock?

The intrinsic value of one IPH stock under the Base Case scenario is 6.12 EUR.

Is IPH stock undervalued or overvalued?

Compared to the current market price of 2.41 EUR, Innate Pharma SA is Undervalued by 61%.